Brokerages Set Elevance Health, Inc. (NYSE:ELV) Price Target at $384.67

Shares of Elevance Health, Inc. (NYSE:ELV) have been assigned an average rating of “Hold” from the twenty-three analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $383.5714.

ELV has been the subject of a number of recent analyst reports. Leerink Partners boosted their price objective on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research report on Thursday, January 29th. Evercore initiated coverage on Elevance Health in a research report on Wednesday, April 8th. They issued a “hold” rating and a $345.00 price objective for the company. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Wolfe Research set a $425.00 price target on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $332.00 price target on shares of Elevance Health in a research report on Thursday, January 29th.

Elevance Health Stock Up 2.3%

Elevance Health stock opened at $323.02 on Tuesday. The stock has a market capitalization of $70.95 billion, a PE ratio of 12.86, a price-to-earnings-growth ratio of 1.74 and a beta of 0.49. Elevance Health has a 12 month low of $273.71 and a 12 month high of $432.93. The business has a 50 day simple moving average of $308.99 and a 200-day simple moving average of $331.91. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts anticipate that Elevance Health will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. The ex-dividend date was Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. Elevance Health’s dividend payout ratio (DPR) is presently 27.39%.

Institutional Trading of Elevance Health

Large investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. increased its position in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares in the last quarter. Rossby Financial LCC increased its position in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares in the last quarter. Activest Wealth Management increased its position in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Elevance Health during the fourth quarter worth approximately $31,000. Finally, J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health during the fourth quarter worth approximately $32,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.